On 31 May 2024, the European Medicines Agency (EMA) published the Committee for Medicinal Products for Human Use (CHMP) reflection paper on Creutzfeldt-Jakob disease (CJD) and plasma-derived and urine-derived medicinal products.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 18-25 May 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, influenza, avian influenza, and cholera.
In 2022, 28 European Union/European Economic Area (EU/EEA) countries reported 39 cases of trichinellosis, which represented a 49% decrease compared with 2021.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 11-17 May 2024 and includes updates on invasive meningococcal disease, an overview of respiratory virus epidemiology in the EU/EEA, cholera and measles.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5–11 May 2024 and includes updates on cholera and western equine encephalitis.
Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.